key: cord-0794514-3j90bwaj
authors: Dee L MacMillan, Kathryn; Morrison, Tierney M.; Melvin, Patrice; Diop, Hafsatou; Gupta, Munish; Wachman, Elisha M.
title: Impact of Coronavirus Disease-2019 on Hospital Care for Neonatal Opioid Withdrawal Syndrome
date: 2022-02-05
journal: J Pediatr
DOI: 10.1016/j.jpeds.2022.02.001
sha: 86735d915d9ac729016e55ade9aebb743f2b82d3
doc_id: 794514
cord_uid: 3j90bwaj

OBJECTIVES: To compare prenatal exposures, hospital care processes, and hospitalization outcomes for opioid-exposed newborns (OENs) before and during the COVID-19 pandemic. STUDY DESIGN: In this multi-center retrospective analysis, data were collected from 19 Massachusetts hospitals including 5 academic and 14 community hospitals. The pre-COVID cohort was defined as births occurring during 3/1/2019-2/28/2020 and the COVID cohort as births during 3/1/2020-12/31/2020. OEN born >/= to 35 weeks gestation were included. Differences in prenatal substance exposures, hospital care processes, and NOWS outcomes including pharmacologic treatment (PharmTx), length of stay (LOS), and as needed (PRN) treatment failure rates were evaluated. RESULTS: There were 663 OEN in the pre-COVID and 476 in the COVID group. No differences between groups were seen in prenatal substance exposures or need for PharmTx. Compared with the pre-COVID group, in the COVID group there were decreases in rooming-in after maternal discharge (63.0% to 53.8%, P=0.001) and care in the pediatric unit setting (25.3% to 23.5%, P=0.001), and increases in LOS (aRR 1.04, 95% CI 1.01-1.08) and breastmilk receipt at discharge (aOR 2.03, 95% CI 1.22-3.39). Within the subset of academic centers, more infants failed PRN treatment in the COVID group [53.8% vs 26.5%, p=0.02; aOR 3.77 (95% CI 0.98-14.5)]. CONCLUSIONS: Among hospitals in our collaborative, hospital processes for NOWS including care setting, rooming-in and LOS were negatively impacted in the COVID group, particularly in academic medical centers.

improvement reports and several small randomized control trials have shown that nonpharmacologic interventions (NPIs) such as rooming-in with parents, increasing parental presence at the bedside, breastmilk receipt, decreasing environmental stimulation and utilizing a variety of soothing techniques improve NOWS outcomes such as need for pharmacologic treatment, length of stay and weight trajectory. [6] [7] [8] [9] [10] . Early recommendations encouraged separating newborns from mother with confirmed or suspected COVID-19 to reduce risk of transmission and potential risks of transmission associated with breastfeeding. 11 As understanding of COVID-19 developed, clinical guidelines have also evolved with greater emphasis on keeping biological parent and baby together and supporting lactation . [12] [13] However, other hospital level policies aimed at infection control may also adversely affect non-pharmacologic care for opioid exposed newborns, including visitor restrictions, loss of volunteer cuddler programs, staff redeployment and conversion of pediatric units into COVID-19 units, decreasing space and opportunities from parental rooming-in. [13] [14] [15] At the same time, during the COVID-19 pandemic there have been increases in reported rates of community substance use and overdoses, reflecting increased social and economic stressors. [16] [17] [18] Although telehealth and updated guidance from the Substance Abuse and Mental Health Services Administration (SAMHSA) provided opportunities for access to medication assisted therapy through take-home dosing, access to other services may have been limited, with a decrease in attendance to group therapy reported among pregnant people in treatment programs for opioid use disorders. [19] [20] [21] Data from the Massachusetts Department of Public Health indicate that rates of NOWS increased from 11.7 to 14 per 1000 live births between 2018 and 2020-2021.

The impact of increased psychosocial stressors on medication for opioid use disorder (MOUD) dosing and unprescribed substance use in pregnancy remains unclear we sought to utilize an J o u r n a l P r e -p r o o f ongoing statewide collaborative seeking to improve the care of families affected by perinatal opioid use to examine the impact of the COVID-19 pandemic on NOWS inpatient care.

This study was conducted under the umbrella of the Massachusetts Perinatal-Neonatal Quality Improvement Network (PNQIN), a statewide quality collaborative that includes birthing hospitals, community organizations, as well as state agencies such as the Department of Children and Families and the Department of Public Health. 22 Since 2016, PNQIN has been involved in leading a NOWS improvement initiative focused on improving NOWS hospitalization outcomes through the increase of non-pharmacologic care measures such as breastmilk receipt and rooming-in. The initiative has included voluntary in-kind participation by multi-disciplinary teams from 37 hospitals across the state of Massachusetts.

Hospitals participating in the PNQIN including a mix of academic medical centers and community hospitals, caring for infants with NOWS in a variety of care settings. The majority of pregnant people with opioid use disorder (OUD) in PNQIN are on MOUD at the time of delivery with methadone, buprenorphine, buprenorphine-naloxone, or naltrexone. 23 There was no uniform monitoring and treatment protocol required for centers for NOWS management, though many centers adapted a family-centered care approached focused on the use of non-pharmacologic care methods with use of the Eat, Sleep, Console (ESC) NOWS Care Tool. 24 Infants were treated with either morphine or methadone as first-line pharmacotherapy, with clonidine or phenobarbital used as second-line agents. Some centers utilized PRN or "as needed" dosing of J o u r n a l P r e -p r o o f opioids. 25 All infants were monitored in the hospital for 24-48 hours after the last dose of morphine or methadone prior to discharge home.

Hospitals participating in the PNQIN collaborative voluntarily enter patient level data into a statewide de-identified REDCap database on a monthly basis. Data points collected include birthing parent demographics, birthing parent drug exposures according to chart review data, birth demographics, details of NOWS care setting and protocol, NOWS pharmacologic treatment details, non-pharmacologic care measures (breastfeeding, rooming-in, skin-to-skin), discharge destination, and re-admissions and ER visits within 30 days of infant discharge. All data are hand abstracted by the hospital teams. This statewide quality improvement project was determined to be non-human subjects research by the institutional review boards at the PNQIN leadership team hospitals. All participating centers completed data use agreements with PNQIN to be able to submit these de-identified data to the secure statewide database.

Inclusion criteria for hospitals to be included in this analysis were complete data entry into REDCap during both the Pre-COVID and COVID periods. The Pre-COVID period was defined as infants born during 3/1/2019 and 2/28/2020, and the COVID period was defined as conducted for the 5 academic medical centers for NOWS outcomes in order to examine potential effects from institutional pressures faced by larger centers converting pediatric spaces to accommodate adult COVID patients in addition to general physical space restrictions and COVID precautions. Process measures and outcome measures were examined by univariate comparisons. Multivariate models were then used to examine determinants of primary outcome measures using mixed-effect logistic regression, including random intercepts for control for clustering by delivery hospital. Variables significantly associated with primary NOWS outcomes (P<0.05) in univariate analyses were included in the regression models. All analyses were performed using SAS statistical software (version 9.4; SAS Institute, Inc).

Of the 37 centers in PNQIN, 26 participated in REDCap data entry to some degree since the start of the database. Of those 26, 7 were excluded from this analysis due to lack of data entry during the COVID time period. This included 3 major academic medical centers and 4 smaller community hospitals that historically had a low volume of NOWS cases. From the remaining 19 centers, there were 1139 parental-infant dyads in our cohort, including 663 in the Pre-COVID and 476 in the COVID group. Five academic medical centers and 14 community hospitals were included, with a mix of Level I, II, and III nurseries. Demographics of our cohort are shown in Table I . There were slight differences in age of the birthing parent, race and ethnicity between the two cohorts. Prenatal substances exposures did not differ significantly with the exception of other opioid exposures in the month prior to delivery ( Table I) Table II . All results were adjusted for clustering by center. There was a significant decrease in rooming-in after parental discharge (63.0% vs 53.8%, p=0.001) in the COVID group, with a decrease in Pediatric Unit care during that time period (25.3% vs 23.5%, p=0.001) ( Table II) . No significant differences in skin-to-skin receipt, breastfeeding eligibility or initiation rates were seen. More infants in the COVID group were assessed with the ESC assessment method (71.6% vs 67.0%, p=0.002). Of the 398 infants who received pharmacologic treatment, 348 (87.4%) were treated with morphine and 44 (11.1%) with methadone per hospital guidelines. In addition, 118 (29.6%) of the 398 treated infants received PRN dosing. Phenobarbital (n=4) and Clonidine (n=1) were utilized as second-line agents. Table II . There were no differences in NOWS PharmTx, LOS, opioid treatment days, PRN dosing failure rates, or receipt of breastmilk at discharge in the Pre-COVID versus COVID groups in bivariate analyses. There were also no differences in our secondary outcomes of hospital re-admissions or ER visits within 30 days, or infant custody status at discharge.

The association of covariates with our primary NOWS outcomes of PharmTx, LOS, and breastmilk receipt at discharge were then examined (data not shown). There were significant differences by center, region, and center level for all primary outcomes. In addition, maternal MOUD was associated with multiple outcomes; specifically, methadone treatment was associated with higher rates of PharmTx and longer LOS and buprenorphine treatment and no MOUD were associated with less PharmTx and shorter LOS. Breastmilk receipt was higher in buprenorphine treated pregnant people and lower in those not on MOUD. Care location was significantly associated with differences, with those cared for within a NICU / SCN having J o u r n a l P r e -p r o o f higher rates of PharmTx and longer LOS, and those cared for at academic centers having higher rates of PharmRx and longer LOS. Male infants had worse NOWS outcomes for both PharmTx and LOS. Exposure to un-prescribed drugs, nicotine, and psychiatric medications were all associated with higher rates of PharmTx, longer LOS, and lower rates of breastmilk receipt at discharge. Any breastmilk receipt during the hospitalization was associated with less PharmTx and shorter LOS.

Our final multivariate regression models for our primary outcome measures for the entire cohort, adjusting for type of center (academic vs non-academic), type of MOUD, care within a NICU/SCN (yes/no), SSRI exposure (yes/no), benzodiazepine exposure (yes/no), and receipt of any breastmilk (yes/no) as well as taking into account hospital level clustering, are shown in Table III . There were no differences in PharmTx between the Pre-COVID and COVID groups.

There was an increase in breastmilk receipt at discharge in the COVID group (aOR 2.03, 95% CI 1.22, 3.39) and an increase in hospital LOS in the COVID group (aRR 1.04, 95% CI 1.01, 1.08).

PRN treatment failure rates did not significantly differ. Table IV . There were no differences in PharmTx or LOS between the Pre-COVID and COVID groups. There was an increase in breastmilk receipt at discharge in the COVID group as seen in the larger cohort (aOR 2.93, 95% CI 1.28, 6.73). For PRN treatment failure rate, the aOR was 3.77 (95% CI 0.98, 14.50) for the COVID group which was no longer statistically significant.

This study demonstrated changes in hospital care processes for newborns with prenatal opioid exposure in the COVID era. Most notably, there was a significant decrease in OEN who roomedin with their parent after hospital discharge. Rooming-in of the parent-infant dyad is an important non-pharmacologic intervention that facilitates parental presence at the bedside and has been associated with improved hospital outcomes for OENs. 7 This decrease in rooming-in following discharge may reflect decreased availability of bedspaces in areas of the hospital where roomingin was not possible as hospital COVID-19 patient load increased. 15 Alternatively, this may reflect the impact of more stringent visitor policies in place to limit COVID-19 spread. Previous studies have demonstrated a negative impact of visitor restrictions on parental presence in the NICU and other pediatric units, as well as on parent experience during their child's hospitalization. [13] [14] [15] [26] [27] In some cases, limitation in number of visitors may have decreased the ability of fathers and other family members or support persons to visit, impacting the feasibility of an extended maternal stay at bedside. In other cases, the change in maternal status from patient to visitor might have precluded her ability to stay overnight with limited visitation hours.

There was also a significant decrease in OENs cared for in pediatric inpatient units.

Presumably this reflects in part decreased availability of bedspaces on these units as hospital COVID-19 census increased. In several locations, adult COVID patients were cared for on units previously designated for pediatric care. 15 This decrease in pediatric unit utilization likely contributed to the decrease in rooming-in post-maternal discharge. Of note, a higher proportion of OENs were cared for at non-academic sites during the COVID time period, and many of these sites do not have inpatient pediatric units available.

Overall NOWS hospitalization outcomes were stable from the pre-COVID to COVID period, with no significant changes to overall rates of pharmacotherapy or any clinically significant differences hospital LOS. A greater proportion of newborns in the COVID period were managed using ESC assessments. This likely reflects a temporal trend as the selection of NOWS assessment model is made at the hospital level, with increased adoption of ESC over time. 24 Management using ESC has been associated with decreased need for pharmacologic treatment and decreased LOS, which may have balanced some of the impact of pandemicassociated decrease in rooming-in and decreased utilization of inpatient pediatric units on care site on these outcomes. 24, [28] [29] [30] [31] As needed, or PRN, opioid dosing for NOWS in combination with non-pharmacologic interventions may be associated with decreased LOS and decreased NICU transfers. 25, 28 Rates of failed PRN dosing and conversion to standing opioids for NOWS treatment increased during the COVID time period in the sub-analysis of academic hospital settings, which may have been more subject to system level pressures as many became dedicated centers for COVID-19 care, converting units in order to accommodate transfers. 15 We hypothesize that the decreased success of limited PRN doses may have been driven by changes in care settings as well as other potential changes in provision of non-pharmacologic care.

There was a significant increase in rates of breastmilk receipt during the COVID period.

This finding was unexpected given prior studies reflected early concern about potential COVID-19 transmission related to breastmilk and demonstrated a decrease in hospital practices supporting breastfeeding. [32] [33] [34] [35] [36] The explanation of this association is uncertain. It is possible that with birthing parents anticipating more time at home, both due to quarantine restrictions, increased availability of remote work for those working from home, and the promise of financial J o u r n a l P r e -p r o o f support for those not working, more mothers felt confident they would be able to maintain a breastfeeding relationship after discharge. 13, [37] [38] It is also possible that some parents may have hoped to provide immunological protection for their newborns. 39 Lastly, there may have been another un-identified temporal trend towards greater breastfeeding education and support within this quality improvement network unrelated to the pandemic over this period of time.

Although previous studies have demonstrated an increase in community rates of opioid use and overdose [16] [17] [18] [19] , our findings did not demonstrate a significant increase in newborns exposed to non-prescribed opioids or other substances. Overall rates of birthing parents on MOUD were stable. Prior studies have documented increased availability of telehealth and takehome dosing. 20, 40 It is possible that improved maternal access to treatment of MOUD provided a balance to other social and financial pressures influencing un-prescribed substance use during the pandemic. Alternatively, there is potential that some cases of prenatal opioid exposure were missed in infants born to parents without previously documented history of substance use disorder or treatment.

Although other studies have looked at the effects of the COVID-19 pandemic on opioid use rates and care of patients with OUD, as well as effects on general pediatric hospital care, to our knowledge this is the first to examine the potential impact of the pandemic specifically on care of the opioid exposed newborn. Strengths of this study include that it covered multiple sites and care settings already routinely entering data on opioid exposed newborns and therefore wellpositioned to capture significant changes over time and included a large number of parentalinfant dyads. Additionally, it included sites with varied approaches to NOWS assessment and management. The baseline characteristics of birthing parents included in the pre-COVID and COVID time period were similar, including overall rates of MOUD and polysubstance exposures J o u r n a l P r e -p r o o f which may influence neonatal outcomes. Of note, the percentage of infants exposed to MOUD in our Massachusetts cohort was higher than the general U.S. population of pregnant individuals with OUD. Given the rates of MOUD remained stable over the pre and post periods and the identical NOWS treatment algorithm for all opioid-exposed infants regardless of type of opioid exposure, our results would still be generalizable to other settings.

There were several limitations to the current study. As this was not a controlled trial, there is potential for other confounders or temporal trends impacting NOWS processes and outcomes in ways we were unable to identify. It is possible that data such as maternal exposure to nicotine was underreported given our reliance of chart abstraction given the limitations of our study design. Not all sites within the PNQIN network continued to enter data during COVID-19. Some enrolled sites had ceased regularly entering data prior to the pandemic, however, it is possible that sites more adversely affected by the pandemic had less staffing capacity to continue to enter data or that sites that did continue to enter data had less infrastructure to support NOWS care in general. Of the seven centers who ceased entering data during COVID, three were major academic medical centers in Boston significantly impacted by COVID-19 patient burden. These centers historically have had a low number of infants with NOWS, thus it is likely that data entry was not a high priority during the COVID surge.

for in a Level 1 baby-only nursery rather than a mother-baby room following maternal discharge versus being transferred to other units. It is also unclear if newborns who might otherwise have been transferred to inpatient pediatric units were kept in mother-baby rooms longer or transferred to level II/III nurseries. Additionally, data regarding birthing parent COVID-19 status at or near delivery were not tracked as part of this study, so we are unable to draw any conclusions about how precautions to prevent transmission from birthing parent to baby may have impacted rooming-in, care site and other hospital processes or NOWS outcome for this subset of dyads. 

Neonatal abstinence syndrome: assessment and management

Neonatal Opioid Withdrawal Syndrome

Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States

Incidence of Neonatal Abstinence Syndrome -28 States

Rural and Urban Differences in Neonatal Abstinence Syndrome and Maternal Opioid Use

A Cost-Effectiveness Analysis of Rooming-in and Breastfeeding in Neonatal Opioid Withdrawal

Volpe Holmes A. Association of Rooming-in With Outcomes for Neonatal Abstinence Syndrome: A Systematic Review and Meta-analysis

Impact of Parental Presence at Infants' Bedside on Neonatal Abstinence Syndrome. Hosp Pediatr

Non-pharmacological care for opioid withdrawal in newborns. Cochrane Database Syst Rev

Maternal breast milk feeding and length of treatment in infants with neonatal abstinence syndrome

Perinatal COVID-19: guideline development, implementation, and challenges

Visitor Guidelines in US Children's Hospitals During COVID-19

Visitor Restriction Policy on Pediatric Wards During Novel Coronavirus (COVID-19) Outbreak: A Survey Study Across North America

Pediatric Hospital Medicine Management, Staffing, and Well-being in the Face of COVID-19

An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19

Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend

Nonfatal Opioid Overdoses at an Urban Emergency Department During the COVID-19 Pandemic

The escalation of the opioid epidemic due to COVID-19 and resulting lessons about treatment alternatives

Leveraging Telehealth in the United States to Increase Access to Opioid Use Disorder Treatment in Pregnancy and Postpartum During the COVID-19

The Colorado Hospitals Substance Exposed Newborn Quality Improvement Collaborative: Standardization of Care for Opioid-Exposed Newborns Shortens Length of Stay and Reduces Number of Infants Requiring Opiate Therapy

A Quality Improvement Initiative to Improve the Care of Infants Born Exposed to Opioids by Implementing the Eat

Reduction in Length of Stay and Morphine Use for NAS With the "Eat, Sleep, Console" Method. Hosp Pediatr

Successful Implementation of the Eat Sleep Console Model of Care for Infants With NAS in a Community Hospital

Breastfeeding of infants born to mothers with COVID-19: a rapid review

Covid-19 and breastfeeding: what's the risk?

When separation is not the answer: Breastfeeding mothers and infants affected by COVID-19. Matern Child Nutr

Experiences of breastfeeding during COVID-19: Lessons for future practical and emotional support. Matern Child Nutr

Implementation of Hospital Practices Supportive of Breastfeeding in the Context of COVID-19 -United States

Breastfeeding during COVID-19: A Narrative Review of the Psychological Impact on Mothers

Social Support During COVID-19: Perspectives of Breastfeeding Mothers

A study of breastfeeding practices, SARS-CoV-2 and its antibodies in the breast milk of mothers confirmed with COVID-19

Telehealth sustains patient engagement in OUD treatment during COVID-19

We would like the acknowledge the Massachusetts Perinatal Neonatal Quality Improvement Network (PNQIN) Perinatal Opioid Project leadership team, particularly Mary Houghton and Allison Doyle, and all participating hospital teams who contributed data towards this project.